Literature DB >> 21878863

Explanatory and pragmatic clinical trials: a primer and application to a recent asthma trial.

David L Sackett1.   

Abstract

Most clinical trials assessing the role of a specific intervention attempt to answer an explanatory question: under ideal circumstances of risk and responsiveness, can the expert care of individual with a particular condition reduce their risks of a relevant but restricted set of outcomes? Such explanatory trials (also called efficacy trials) are of direct relevance to expert clinicians and their highly compliant patients. Another question, potentially of broader clinical or health care policy relevance is: Does this treatment improve patient-important outcomes when applied by typical clinicians to typical patients? Answering this latter question is the goal of pragmatic trial, also labeled by some as "management" or "effectiveness" trial. The methodological and organizational differences between explanatory and pragmatic trials include, among others, patients eligibility (restricted to highly responsive and compliant patients in explanatory trials vs. everyone with condition of interest in pragmatic trials), experimental and comparator intervention (blinded and inflexible with strict instructions vs. flexible with cross-over permitted and no blinding), types of practitioners (only those with documented high expertise vs. all who usually provide given mode of care), and outcome measurement (often limited to biologic effects vs. broad overall health effects sometimes based on administrative data bases on mortality and utilization). Those aspects of study design and conduct and their role in determining a place of an intervention in clinical practice are reviewed in this paper.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21878863

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  10 in total

1.  'Pragmatic' and 'explanatory' attitudes to randomised trials.

Authors:  Merrick Zwarenstein
Journal:  J R Soc Med       Date:  2017-05       Impact factor: 5.344

2.  Ensuring continuity of patient care across the healthcare interface: Telephone follow-up post-hospitalization.

Authors:  Mohanad Odeh; Claire Scullin; Glenda Fleming; Michael G Scott; Robert Horne; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2019-01-24       Impact factor: 4.335

Review 3.  The role of pragmatic clinical trials in the evolution of learning health systems.

Authors:  Gary E Rosenthal
Journal:  Trans Am Clin Climatol Assoc       Date:  2014

4.  The PRECIS-2 tool seems not to be useful to discriminate the degree of pragmatism of medicine masked trials from that of open-label trials.

Authors:  Rafael Dal-Ré
Journal:  Eur J Clin Pharmacol       Date:  2020-10-26       Impact factor: 2.953

5.  Regional interdependence and manual therapy directed at the thoracic spine.

Authors:  Amy McDevitt; Jodi Young; Paul Mintken; Josh Cleland
Journal:  J Man Manip Ther       Date:  2015-07

Review 6.  Comparing Randomized Controlled Trials and Real-World Studies in Chronic Obstructive Pulmonary Disease Pharmacotherapy.

Authors:  Donald P Tashkin; Alpesh N Amin; Edward M Kerwin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-06-02

7.  Pilot and feasibility studies in exercise, physical activity, or rehabilitation research.

Authors:  Rasha El-Kotob; Lora M Giangregorio
Journal:  Pilot Feasibility Stud       Date:  2018-08-14

8.  Pragmatic trials and implementation science: grounds for divorce?

Authors:  Ray Pawson
Journal:  BMC Med Res Methodol       Date:  2019-08-16       Impact factor: 4.615

9.  An explanatory randomised placebo controlled trial of levothyroxine supplementation for babies born <28 weeks' gestation: results of the TIPIT trial.

Authors:  Sze M Ng; Mark A Turner; Carrol Gamble; Mohammed Didi; Suresh Victor; Donal Manning; Paul Settle; Richa Gupta; Paul Newland; Alan Michael Weindling
Journal:  Trials       Date:  2013-07-11       Impact factor: 2.279

10.  Blinding in pharmacological trials: the devil is in the details.

Authors:  Mandy Wan; Mine Orlu-Gul; Helene Legay; Catherine Tuleu
Journal:  Arch Dis Child       Date:  2013-07-29       Impact factor: 3.791

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.